87
Future Developments in Radiation Therapy for Prostate Cancer Steven J. Frank, MD Assistant Professor Genitourinary and Head/Neck Sections Division of Radiation Oncology

Future Developments In Radiation Therapy For Prostate Cancer

Embed Size (px)

Citation preview

Page 1: Future Developments In Radiation Therapy For Prostate Cancer

Future Developments in

Radiation Therapy for Prostate

Cancer

Steven J. Frank, MD

Assistant Professor

Genitourinary and Head/Neck Sections

Division of Radiation Oncology

Page 2: Future Developments In Radiation Therapy For Prostate Cancer

Rectal Fistula

Sinus tract vs fistula

Page 3: Future Developments In Radiation Therapy For Prostate Cancer

Rectal Necrotic Tissue

Biopsies showed

necrotic tissue

Page 4: Future Developments In Radiation Therapy For Prostate Cancer

Dose-escalation is not free

• Rectal toxicity

• Urinary

• Erectile

Page 5: Future Developments In Radiation Therapy For Prostate Cancer

Therapeutic ratio

Tumor control

Normal tissue complication

Total Radiation DOSE

Probability

of

EFFECT

Page 6: Future Developments In Radiation Therapy For Prostate Cancer

Where are we going in

Prostate Radiation Therapy?

EBRT

• 2D

• 3D

• IMRT

• Hypofractionation

• SBRT

• Protons

• IMPT

Brachytherapy

• 1st Generation Implants

• 2nd Generation Implants

• 3rd Generation Implants

• 4th Generation Implants

• 5th Generation Implants

Page 7: Future Developments In Radiation Therapy For Prostate Cancer

Where have we come from?

Page 8: Future Developments In Radiation Therapy For Prostate Cancer

PSA control after conventional

dose RT (~70Gy)

IJROBP 2001;49

Page 9: Future Developments In Radiation Therapy For Prostate Cancer

Higher RT doses improve

disease control

• Multiple retrospective studies show benefit to

higher doses of RT.

– MDACC (Pollack & Zagars. IJROBP 39, 1997)

– Fox Chase (Hanks et al. IJROBP 41, 1998)

– MSKCC (Zelefsky et al. IJROBP 41, 1998)

– MSKCC (Zelefsky et al. J Urol 166, 2001)

– Cleveland Clinic (Lyons et al. Urol 55, 2000)

Page 10: Future Developments In Radiation Therapy For Prostate Cancer

More Grade 2 rectal complications in 78 Gy arm

[IJROBP 53, 2002]

Page 11: Future Developments In Radiation Therapy For Prostate Cancer

More Grade 2+ rectal toxicity

if >25% of rectum received 70Gy

Page 12: Future Developments In Radiation Therapy For Prostate Cancer

Dose-escalation w/ less

toxicity• Delivery techniques

– IMRT

– Protons

• Reduce PTV– Target localization (e.g. BAT, fiducial markers)

– Target immobilization (e.g. rectal balloon)

– Reduce CTV

• Selective dose-escalation– Intra-prostatic targets and avoidance structures

Page 13: Future Developments In Radiation Therapy For Prostate Cancer

Axial Dose Distribution

75.6 Gy

60 Gy79 Gy

Page 14: Future Developments In Radiation Therapy For Prostate Cancer

Sagittal Dose Distribution

Page 15: Future Developments In Radiation Therapy For Prostate Cancer

Prostate:

>100%[email protected]

SV:

>95%[email protected]

Rectum:

<20%V@70Gy

<35%V@60Gy

Bladder:

<25%V@70Gy

<35%V@60Gy

Femoral Heads:

<5%V@50Gy

DVH

Page 16: Future Developments In Radiation Therapy For Prostate Cancer

MSKCC

Rectal toxicity (3D CRT vs. IMRT)

3DCRT

IMRT

Page 17: Future Developments In Radiation Therapy For Prostate Cancer

MSKCCGU toxicity based on dose 81 vs. 86 Gy

“Among patients who received doses 75.6 Gy, the incidence

of Grade 2 urinary symptoms at 5 years was 13% compared 8%

at lower doses.” [IJROBP 53, 2002]

Page 18: Future Developments In Radiation Therapy For Prostate Cancer

Dose-escalation w/ less

toxicity• Delivery techniques

– IMRT

– Protons

• Reduce PTV

– Target localization (e.g. BAT, fiducials)

– Target immobilization (e.g. rectal balloon, tracking)

– Reduce CTV

• Selective dose-escalation

Page 19: Future Developments In Radiation Therapy For Prostate Cancer

21

Page 20: Future Developments In Radiation Therapy For Prostate Cancer

Accelerator Systems

Linac Injector

Synchrotron

Page 21: Future Developments In Radiation Therapy For Prostate Cancer

13 m diameter190 tons SAD 2.7 m

Page 22: Future Developments In Radiation Therapy For Prostate Cancer

Nozzle

Snout

Couch

Image

Receptors

X-ray

tube

Articulating Floor

Page 23: Future Developments In Radiation Therapy For Prostate Cancer

A Single Bragg Peak

Page 24: Future Developments In Radiation Therapy For Prostate Cancer

Modulation of the Bragg Peak

The Bragg peak is spread out by introducing extra absorbing material before the beam enters the patient. If different thickness of such absorber are present for different fractions of the irradiation time, the narrow monoenergetic peak can be spread into a useful plateau

The Bragg peak can be spread out

to a useful plateau by the use of a

rotating stepped absorber.

Range

Modulator

Wheel

Page 25: Future Developments In Radiation Therapy For Prostate Cancer

SOBP, Photons, & Bragg Peak

PSI

Page 26: Future Developments In Radiation Therapy For Prostate Cancer

Aperture 2D Shaping

Lateral aspect of aperture used

to spare critical structures

Page 27: Future Developments In Radiation Therapy For Prostate Cancer

Compensator 3D Distal

Shaping

As well as spreading out

the Bragg peak, the final

range itself must be

shaped to the distal

surface of the target

volume taking into account

heterogeneities

Page 28: Future Developments In Radiation Therapy For Prostate Cancer

Two lateral beams.

Further improvements w/ IMPT?

Decreased integral dose.

Better dose homogeneity.

Quicker planning time.

Page 29: Future Developments In Radiation Therapy For Prostate Cancer

Dose-escalation w/ less toxicity

• Delivery techniques

– IMRT

– Protons

• Reduce PTV

– Target localization (e.g. BAT, fiducials)

– Target immobilzation (e.g. rectal balloon)

• Selective dose-escalation

Page 30: Future Developments In Radiation Therapy For Prostate Cancer

Sharp dose-fall off with IMRT requires

accurate DAILY target localization

Page 31: Future Developments In Radiation Therapy For Prostate Cancer

25 treatment CTs

Acquired during a course

of 42 fxs treatment

Dancing Prostate

Dong (MDA), 2002

Page 32: Future Developments In Radiation Therapy For Prostate Cancer

IGRT is a Process

VARIAN

Page 33: Future Developments In Radiation Therapy For Prostate Cancer

Reducing PTV a.k.a.

IGRT (Image Guided Radation Therapy)

• Improve accuracy and decrease normal

tissue irradiated

• Requires daily imaging of the target

• INTER-fractional movement

• INTRA-fractional movement

Page 34: Future Developments In Radiation Therapy For Prostate Cancer

IGRT

• Portal imaging

• Ultrasound (e.g. B.A.T.)

• Fiducial markers (intraprostatic)

• Volumetric on-board imaging

– In-room CT

– Cone-beam CT

Page 35: Future Developments In Radiation Therapy For Prostate Cancer

BAT alignment (axial)

Bladder

Prostate

Rectum

Page 36: Future Developments In Radiation Therapy For Prostate Cancer

BAT Alignment (sagittal)

Bladder

Prostate

Rectum

Page 37: Future Developments In Radiation Therapy For Prostate Cancer

Ultrasound-based alignment

• Pros– Non-invasive

– Reasonably good alignment

– Visualize SV/ bladder/rectum

– Visualize prostate surface contour

– Follow-up

– New volumetric systems

• Cons

– User-subjectivity

– Patient anatomy may

affect image quality

– Impact of probe

pressure on prostate

position

– Different imaging

modality

Page 38: Future Developments In Radiation Therapy For Prostate Cancer
Page 39: Future Developments In Radiation Therapy For Prostate Cancer
Page 40: Future Developments In Radiation Therapy For Prostate Cancer

On-Board Imager (OBI) - Varian

kV X-ray Source

aSi Imaging Panel

(2048 x 1536 pixel resol.)

Robotic Arms

- 3 pivot points

- Completely retractable

- Position feedback control

Software

- Image acquisition and registration

Page 41: Future Developments In Radiation Therapy For Prostate Cancer

OBI 2D-2D manual match: pre-shift

Page 42: Future Developments In Radiation Therapy For Prostate Cancer

OBI 2D-2D manual match: postshift

Page 43: Future Developments In Radiation Therapy For Prostate Cancer

Fiducial-based alignment

• Pros– Less subjectivity

– Good alignment

– Allows target tracking

• Kitamura and Shirato et al.

– Better for large patients

– Basis for improved multimodality image fusion (e.g. MRI-CT)

– Ongoing MDACC study comparing fiducials vs. CT-on-rails

• Cons– Invasive

– Requires daily ports

• (unless KV imaging onboard)

– No image of SV, rectum/bladder

– No image of prostate surface contour

– Shifts may not be representative of volume

• Jaffray et al. ASTRO 2004

• Fiducials and MRI

• 47% had 3mm deformation over 90% of surface

• On average, 14% of surface deformed by >3mm (up to 9mm)

Page 44: Future Developments In Radiation Therapy For Prostate Cancer

Varian ExaCT™ at MDACC

In-room CT Linac

Page 45: Future Developments In Radiation Therapy For Prostate Cancer

CAT Software (3D-3D matching)

Compares Pinnacle planed patients

to volumetric images

Lei Dong, Lifei (Joy) Zhang

Page 46: Future Developments In Radiation Therapy For Prostate Cancer

A closer look at contour overlay

Courtesy of Lei Dong

Page 47: Future Developments In Radiation Therapy For Prostate Cancer

Step 4. Automatic Image Registration

Courtesy of Lei Dong

Page 48: Future Developments In Radiation Therapy For Prostate Cancer

Step 5. Review Image Registration

(prostate is the target of alignment)

Courtesy of Lei Dong

Page 49: Future Developments In Radiation Therapy For Prostate Cancer

• CT-based alignment could yield

accuracy of <3mm

– Smaller treatment margins

– Less dose to rectum, bladder

– Avoid high-dose to intra-prostatic

structures (e.g. urethra)

Page 50: Future Developments In Radiation Therapy For Prostate Cancer

Robotic arm motion

Page 51: Future Developments In Radiation Therapy For Prostate Cancer

Robotic arm motion

Page 52: Future Developments In Radiation Therapy For Prostate Cancer

Robotic arm motion

Page 53: Future Developments In Radiation Therapy For Prostate Cancer

Cone-beam CT

• Uses on board kV X-ray source and

amorphous silicon flat panel imager

• Large field of view (25 x 25 x 10 cm) and

single revolution captures images

– Unlike standard CT that uses small field of view

and many revolutions

• Inferior image quality compared to

conventional CT but may be adequate for RT

targeting

Page 54: Future Developments In Radiation Therapy For Prostate Cancer

Cone Beam CT – Large GU patient

(330 lbs)

CBCT Planning CT

Page 55: Future Developments In Radiation Therapy For Prostate Cancer

Post shift CBCT verification

using in-house CAT software

Page 56: Future Developments In Radiation Therapy For Prostate Cancer

Cone Beam CT vs. CT on Rails

< 5 min acquisition and

reconstruction time

Patient is rotated into scanning

position on treatment couch (lateral

and vertical shifts required)

Isocenter not linked to images

Each slice is a 1 sec time average

50 cm FOV (full scan)

< 5 min acquisition and

reconstruction time

Patient is imaged in treatment

position (except for lateral shifts)

Isocenter defined in CT space

Each slice is a 60 sec time average

45 cm FOV half-scan

Page 57: Future Developments In Radiation Therapy For Prostate Cancer

Dose-escalation w/ less toxicity

• Delivery techniques

– IMRT

– Protons

• Reduce PTV

– Target localization (e.g. BAT, fiducials)

– Target immobilzation (e.g. rectal balloon)

• Selective dose-escalation

– Intraprostatic GTV/OAR

Page 58: Future Developments In Radiation Therapy For Prostate Cancer

Endo-rectal balloon

1. Immobilize prostate (accounts for inter-

and intrafractional motion)

2. Displaces rectum away from high dose

Page 59: Future Developments In Radiation Therapy For Prostate Cancer

Shifts Detected By CT and BAT

-2.0

-1.5

-1.0

-0.5

0.0

0.5

1.0

1.5

2.0

-2.0 -1.5 -1.0 -0.5 0.0 0.5 1.0 1.5 2.0

CT Shift (cm)

BA

T S

hif

t (c

m)

RL

AP

SI No call

by BAT

Planning CT Sagittal

Same Day Sagittal CT

Same Day Axial CT

BAT Oblique Axial Sagittal

One Patient

Example

Sup.

Sup.

Page 60: Future Developments In Radiation Therapy For Prostate Cancer

Is intra-fractional prostate motion a

concern?

• Daily IMRT treatment 15 minutes to setup and deliver

• Possible prostate positional change during this interval largely due to transient rectal gas

• Positional change can be large (>5 mm), but usually transient

• Clinical impact over 7-8 week treatment course is unknown

Page 61: Future Developments In Radiation Therapy For Prostate Cancer

Dose-escalation w/ less toxicity

• Delivery techniques

– IMRT

– Protons

• Reduce PTV

– Target localization (e.g. BAT, fiducials)

– Target immobilzation (e.g. rectal balloon)

• Selective dose-escalation

– Intraprostatic GTV/OAR

Page 62: Future Developments In Radiation Therapy For Prostate Cancer

What is needed to treat intra-

prostatic targets?

• Imaging modality beyond CT that can delineate intra-prostatic tumor– Endorectal MRI/MRS

– Dynamic contrast MRI

• Conformal delivery method– IMRT, protons, brachytherapy

• Accurate delivery– Daily imaging w/ online correction

– Target immobilization?

– Transrectal U/S guidance

Page 63: Future Developments In Radiation Therapy For Prostate Cancer

Endorectal MRI

• Endorectal MRI uses a coil inside an inflatable latex balloon (50-70cc).– Coil just posterior to

prostate

• Resolution is 0.4mm per pixel pair– Body coil MRI has

resolution of 3 mm

• Accuracy is technique and reader dependent as per RDOG studies

– [Radiology 1994;192:47-54]

[Roach et al. Oncology 15:1399-1410]

Page 64: Future Developments In Radiation Therapy For Prostate Cancer
Page 65: Future Developments In Radiation Therapy For Prostate Cancer
Page 66: Future Developments In Radiation Therapy For Prostate Cancer

Special thanks to Danny Tran & Lei Dong

75.6Gy

87.2Gy

Concomitant

boost

Page 67: Future Developments In Radiation Therapy For Prostate Cancer

CT/ MRI/MRS fusion

• Define CTV more clearly

– Prostate anatomy

– Reduced side effects

• Define other CTV’s (e.g. peripheral zone, urethra)

– Selective dose-escalation (“Dose painting”)

– Reduce toxicity w/ in the prostate

• Define GTV

– Selective dose-escalation (Focal boost)

Page 68: Future Developments In Radiation Therapy For Prostate Cancer

Hypofractionation

• Provide basis for larger fractional dose w/

equal or less toxicity

– / for prostate ca may be < 4 Gy» [Brenner et al. IJROBP 52:6-13]

• Hypofractionation studies:

– Kupelian et al 70 Gy (2.5Gy/Fxn) [IJROBP 53, 2002]

– MDACC ongoing randomized study

• 75.6/1.8 Gy vs. 72/2.4 Gy (BED = 78-82 Gy)

Page 69: Future Developments In Radiation Therapy For Prostate Cancer

72 Gy (2.4Gy)

Page 70: Future Developments In Radiation Therapy For Prostate Cancer

Cleveland Clinic-retrospective70Gy/2.5Gy vs. 78Gy/2Gy

Grade 2-3 rectal toxicity

Kupelian et al. IJROPB 53, 2002

166 (SCIMRT)

116 (3DCRT)

Median FU 21 vs. 32 mo

Only 2 pts in each group

had Gr 2+ GU toxicity.

Page 71: Future Developments In Radiation Therapy For Prostate Cancer

Highest Degree of Conformal

Therapy?

Brachytherapy

Page 72: Future Developments In Radiation Therapy For Prostate Cancer

1st Generation Implants:

Open Placement

Page 73: Future Developments In Radiation Therapy For Prostate Cancer

Transperineal Interstitial Permanent

Prostate Brachytherapy

Ultrasound probe in

rectum for needle guidance

Perineal template to

localize needles as planned

18 gauge needle

(1.3 mm diam) for

seed placement

Page 74: Future Developments In Radiation Therapy For Prostate Cancer

2nd Generation Implants:

Uniform Loading

Page 75: Future Developments In Radiation Therapy For Prostate Cancer

Source Migration

Davis BJ et al., J Urol 2002; 168:1103.

*

*Coronary

artery

Page 76: Future Developments In Radiation Therapy For Prostate Cancer

3rd Generation Implants

• Modified peripheral loading

– Reduced urethral dose (not urethral sparing)

– All seeds implanted in the prostate

(which means little treatment outside capsule

or high urethral dose with margin)

– CT-based dosimetry evaluation

Page 77: Future Developments In Radiation Therapy For Prostate Cancer

Modified Peripheral Loading

Page 78: Future Developments In Radiation Therapy For Prostate Cancer

4th Generation Implants

• Stranded seeds (Varistrand )

– Less seed migration

– Permits periprostatic seed placement

• Improved dosimetry

– Wider therapeutic margin on prostate (3 - 5

mm)

– MRI / CT fusion (better QA better implants)

– Improved Homogeneity

Page 79: Future Developments In Radiation Therapy For Prostate Cancer

Intraoperative Comparison of Actual Seed Location to Preplan

Page 80: Future Developments In Radiation Therapy For Prostate Cancer

PTV DVH Parameters

V100>95%

V150<60%

V200<20%D90<120%

R100<1cc

Page 81: Future Developments In Radiation Therapy For Prostate Cancer

5 yr BRFS Monotherapy

• Seed monotherapy 5 yr BRFS if implant

quality questionable or poor = 34-63%

• Seed monotherapy 5 yr BRFS if implant

quality is good = 82-98%

• % positive Bx cores predicts RP BRFS

• RTOG-0232 randomized study I125/Pd103 +/-

EBRT intermediate risk patients

Page 82: Future Developments In Radiation Therapy For Prostate Cancer

Transperineal Interstitial

Permanent Brachytherapy

Alone for Selected Patients

with Intermediate Risk

Prostate Cancer

Phase II Prospective Single Arm Study

David Swanson and Steven J. Frank

Page 83: Future Developments In Radiation Therapy For Prostate Cancer

Stratification

• < 35% core biopsy and Gleason 7 disease

with a PSA under 10

• < 35% core biopsy and combined Gleason

scores less than 7 with a PSA 10-15

• >/= 35% core biopsy and Gleason 7 disease

with a PSA under 10

• >/= 35% core biopsy and combined Gleason

scores less than 7 with a PSA 10-15

Page 84: Future Developments In Radiation Therapy For Prostate Cancer

MRI vs. CT

July 2008

Front view Front view

Notice the artifacts on CT imaging

Prostate Phantom Prostate Phantom

Page 85: Future Developments In Radiation Therapy For Prostate Cancer

1.5T MRI Strand

Prostate Phantom

C4

Seed

Prostate Phantom

Oblique view Saggittal view

Page 86: Future Developments In Radiation Therapy For Prostate Cancer
Page 87: Future Developments In Radiation Therapy For Prostate Cancer

GU Team

• Physicians

– Seungtaek Choi

– Min Rex Cheung

– Deborah A. Kuban

– Andrew K. Lee

– Jim D. Cox

– Tom A. Buchholz

• Physicists

– Lei Dong

– Rajat Kudchadker

– Jennifer Johnson

• Dosimetrists

– Paula Berner

– Teresa Bruno

– Mandy Cunningham

• Therapists

• Nurses